Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Abstract Text:

Alessandro Gringeri,Pier Mannuccio Mannucci,

It has been suggested that plasma-derived factor VIII products induce fewer inhibitors than recombinant factor VIII products. We investigated the relationship of factor VIII product type and switching between factor VIII products with the risk to develop inhibitors. This multicenter retrospective cohort study included 316 patients with severe hemophilia A born between 1990 and 2000. The outcome was clinically relevant inhibitor development, defined as the occurrence of at least 2 positive inhibitor titers with decreased recovery. The risk of inhibitor development was not clearly lower in plasma-derived compared with recombinant factor VIII products (relative risk [RR], 0.8; 95% confidence interval [CI], 0.5-1.3). Among high-titer inhibitors, the possible reduction in risk was even less pronounced (RR, 0.9; CI, 0.5-1.5). Plasma-derived products with considerable quantities of von Willebrand factor (VWF) carried the same risk for inhibitor development as recombinant factor VIII products (RR, 1.0; CI, 0.6-1.6). Switching between factor VIII products did not increase the risk for inhibitors (RR, 1.1; CI, 0.6-1.8). In conclusion, our findings support neither the notion that plasma-derived factor VIII products with considerable concentrations of VWF confer a lower risk to develop inhibitory antibodies than recombinant factor VIII products, nor that switching between factor VIII product brands increases inhibitor risks in previously untreated patients with severe hemophilia A.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Publishing Authors By Initials

A Gringeri,PM Mannucci,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Blood

VOLUME: 109

Page Numbers: 4693-7

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 11

MONTH: 01

YEAR: 2007

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Information

Substance Name: Factor VIII

Registry Number: 9001-27-8

Grant and Affiliation Information for Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

AFFILIATION: Van Creveldlkiniek, University Medical Center Utrrecht, Utrecht, The Netherlands.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE: Blood. 2007 Oct 15;110(8):3084; author r

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study Related Publications

• Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content.
• Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options.
• Collision judgment of objects approaching the head.
• Communication between the corpus cavernosum penis and the corpus spongiosum penis in a bull diagnosed by modified contrast cavernosography: A case report.
• Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation.
• Delayed intrauterine repair of an experimental spina bifida with a collagen biomatrix.
• Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation.
• Energy conversion in microsystems: is there a role for micro/nanofluidics?
• Flash suppression and flash facilitation in binocular rivalry.
• Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device.
• HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.
• High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.
• ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.
• Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.
• Lifetime occupation, education, smoking, and risk of ALS.
• Media exposure, mood, and body image dissatisfaction: an experimental test of person versus product priming.
• Multiphase flow in microfluidic systems --control and applications of droplets and interfaces.
• Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study.
• Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage.
• Pivotal role of ChIFNgamma in the pathogenesis and immunosuppression of infectious bursal disease.
• RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia.
• Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
• Redox cycling with facing interdigitated array electrodes as a method for selective detection of redox species.
• Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis.
• Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage.
• Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
• Shared risk and protective factors for overweight and disordered eating in adolescents.
• Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints.
• Structural insight into OprD substrate specificity.
• Vascular events after liver transplantation: a long-term follow-up study.